An Overview on Different L-Thyroxine (l-T4) Formulations and Factors Potentially Influencing the Treatment of Congenital Hypothyroidism During the First 3 Years of Life
- PMID: 35757415
- PMCID: PMC9218053
- DOI: 10.3389/fendo.2022.859487
An Overview on Different L-Thyroxine (l-T4) Formulations and Factors Potentially Influencing the Treatment of Congenital Hypothyroidism During the First 3 Years of Life
Abstract
Congenital hypothyroidism (CH) is a relatively frequent congenital endocrine disorder, caused by defective production of thyroid hormones (THs) at birth. Because THs are essential for the development of normal neuronal networks, CH is also a common preventable cause of irreversible intellectual disability (ID) in children. Prolonged hypothyroidism, particularly during the THs-dependent processes of brain development in the first years of life, due to delays in diagnosis, inadequate timing and dosing of levothyroxine (l-thyroxine or l-T4), the non-compliance of families, incorrect follow-up and the interference of foods, drugs and medications affecting the absorption of l-T4, may be responsible for more severe ID. In this review we evaluate the main factors influencing levels of THs and the absorption of l-T4 in order to provide a practical guide, based on the existing literature, to allow optimal follow-up for these patients.
Keywords: L-thyroxine (L-T4); central nervous system; children; congenital hypothyroidism; pharmacological interferences; plastic period.
Copyright © 2022 Stagi, Municchi, Ferrari and Wasniewska.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
The different requirement of L-T4 therapy in congenital athyreosis compared with adult-acquired hypothyroidism suggests a persisting thyroid hormone resistance at the hypothalamic-pituitary level.Eur J Endocrinol. 2014 Nov;171(5):615-21. doi: 10.1530/EJE-14-0621. Eur J Endocrinol. 2014. PMID: 25305309
-
Treatment of congenital hypothyroidism: comparison between L-thyroxine oral solution and tablet formulations up to 3 years of age.Eur J Endocrinol. 2021 Nov 30;186(1):45-52. doi: 10.1530/EJE-20-1444. Eur J Endocrinol. 2021. PMID: 34714772
-
Non-inferiority of liquid thyroxine in comparison to tablets formulation in the treatment of children with congenital hypothyroidism.J Pediatr Endocrinol Metab. 2021 Oct 18;35(2):239-247. doi: 10.1515/jpem-2021-0458. Print 2022 Feb 23. J Pediatr Endocrinol Metab. 2021. PMID: 34653328 Clinical Trial.
-
Congenital hypothyroidism.Orphanet J Rare Dis. 2010 Jun 10;5:17. doi: 10.1186/1750-1172-5-17. Orphanet J Rare Dis. 2010. PMID: 20537182 Free PMC article. Review.
-
Diagnosis, treatment and outcome of congenital hypothyroidism.Endocr Dev. 2014;26:50-9. doi: 10.1159/000363155. Epub 2014 Aug 29. Endocr Dev. 2014. PMID: 25231444 Review.
Cited by
-
Comparison between Liquid and Tablet Formulations in the Treatment of Congenital Hypothyroidism up to 3 Years of Age: The First Italian Study.Children (Basel). 2024 Sep 19;11(9):1136. doi: 10.3390/children11091136. Children (Basel). 2024. PMID: 39334669 Free PMC article.
-
Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status.Int J Mol Sci. 2023 Jun 14;24(12):10114. doi: 10.3390/ijms241210114. Int J Mol Sci. 2023. PMID: 37373261 Free PMC article. Review.
-
Worsening of Congenital Hypothyroidism After Start of Carob-bean Gum Thickened Formula: Is There a Link? A Case Report.J Clin Res Pediatr Endocrinol. 2025 May 27;17(2):237-241. doi: 10.4274/jcrpe.galenos.2023.2023-9-12. Epub 2023 Dec 6. J Clin Res Pediatr Endocrinol. 2025. PMID: 38054412 Free PMC article.
References
-
- Bowden SA, Goldis M. Congenital Hypothyroidism. 2021. In: StatPearls [Internet]. Treasure Island (FL: StatPearls Publishing; (2021). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources